These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 19506475)

  • 1. Dopamine agonists and valvular heart disease.
    Cheung D; Heaney A
    Curr Opin Endocrinol Diabetes Obes; 2009 Aug; 16(4):316-20. PubMed ID: 19506475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease.
    Antonini A; Poewe W
    Lancet Neurol; 2007 Sep; 6(9):826-9. PubMed ID: 17706566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma.
    Kars M; Delgado V; Holman ER; Feelders RA; Smit JW; Romijn JA; Bax JJ; Pereira AM
    J Clin Endocrinol Metab; 2008 Sep; 93(9):3348-56. PubMed ID: 18559921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cabergoline therapy for prolactinomas: is valvular heart disease a real safety concern?
    Vallette S; Serri K; Serri O
    Expert Rev Cardiovasc Ther; 2010 Jan; 8(1):49-54. PubMed ID: 20014934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists.
    Kim JY; Chung EJ; Park SW; Lee WY
    Mov Disord; 2006 Aug; 21(8):1261-4. PubMed ID: 16685692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Review#: Potential cardiac valve effects of dopamine agonists in hyperprolactinemia.
    Valassi E; Klibanski A; Biller BM
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1025-33. PubMed ID: 20130078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required.
    Kars M; Pereira AM; Bax JJ; Romijn JA
    Eur J Endocrinol; 2008 Oct; 159(4):363-7. PubMed ID: 18703568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal effective doses of cabergoline and bromocriptine and valvular leasions in men with prolactinomas.
    Yarman S; Kurtulmus N; Bilge A
    Neuro Endocrinol Lett; 2012; 33(3):340-6. PubMed ID: 22635095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cabergoline use for pituitary tumors and valvular disorders.
    Auriemma RS; Pivonello R; Ferreri L; Priscitelli P; Colao A
    Endocrinol Metab Clin North Am; 2015 Mar; 44(1):89-97. PubMed ID: 25732645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine agonists and cardiac valvulopathy in Parkinson disease: a case-control study.
    Yamamoto M; Uesugi T; Nakayama T
    Neurology; 2006 Oct; 67(7):1225-9. PubMed ID: 17030757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in heart valve structure and function in patients treated with dopamine agonists for prolactinomas, a 2-year follow-up study.
    Delgado V; Biermasz NR; van Thiel SW; Ewe SH; Marsan NA; Holman ER; Feelders RA; Smit JW; Bax JJ; Pereira AM
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):99-105. PubMed ID: 22211510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline.
    Kenangil G; Ozekmekçi S; Koldas L; Sahin T; Erginöz E
    Clin Neurol Neurosurg; 2007 May; 109(4):350-3. PubMed ID: 17307289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of patients with macroprolactinomas initially treated with dopamine agonists.
    Kars M; Pereira AM; Smit JW; Romijn JA
    Eur J Intern Med; 2009 Jul; 20(4):387-93. PubMed ID: 19524180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin excess: treatment and toxicity.
    Gillam MP; Fideleff H; Boquete HR; Molitch ME
    Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bromocriptine use and the risk of valvular heart disease.
    Tan LC; Ng KK; Au WL; Lee RK; Chan YH; Tan NC
    Mov Disord; 2009 Feb; 24(3):344-9. PubMed ID: 18989898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased prevalence of subclinical cardiac valve fibrosis in patients with prolactinomas on long-term bromocriptine and cabergoline treatment.
    Elenkova A; Shabani R; Kalinov K; Zacharieva S
    Eur J Endocrinol; 2012 Jul; 167(1):17-25. PubMed ID: 22511808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update in prolactinomas.
    Kars M; Dekkers OM; Pereira AM; Romijn JA
    Neth J Med; 2010 Mar; 68(3):104-12. PubMed ID: 20308704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease?].
    Roth J; Ulmanová O; Růzicka E
    Cas Lek Cesk; 2005; 144(2):123-6. PubMed ID: 15807300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The need for annual echocardiography to detect cabergoline-associated valvulopathy in patients with prolactinoma: a systematic review and additional clinical data.
    Caputo C; Prior D; Inder WJ
    Lancet Diabetes Endocrinol; 2015 Nov; 3(11):906-13. PubMed ID: 25466526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.